RT Journal Article
SR Electronic
T1 Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.25.20237883
DO 10.1101/2020.11.25.20237883
A1 Yogiraj Ray
A1 Shekhar Ranjan Paul
A1 Purbita Bandopadhyay
A1 Ranit D’Rozario
A1 Jafar Sarif
A1 Abhishake Lahiri
A1 Debaleena Bhowmik
A1 Janani Srinivasa Vasudevan
A1 Ranjeet Maurya
A1 Akshay Kanakan
A1 Sachin Sharma
A1 Manish Kumar
A1 Praveen Singh
A1 Rammohan Roy
A1 Kausik Chaudhury
A1 Rajsekhar Maiti
A1 Saugata Bagchi
A1 Ayan Maiti
A1 Md. Masoom Perwez
A1 Abhinandan Mondal
A1 Avinash Tewari
A1 Samik Mandal
A1 Arpan Roy
A1 Moumita Saha
A1 Durba Biswas
A1 Chikam Maiti
A1 Sayantan Chakraborty
A1 Biswanath Sharma Sarkar
A1 Anima Haldar
A1 Bibhuti Saha
A1 Shantanu Sengupta
A1 Rajesh Pandey
A1 Shilpak Chatterjee
A1 Prasun Bhattacharya
A1 Sandip Paul
A1 Dipyaman Ganguly
YR 2020
UL http://medrxiv.org/content/early/2020/11/29/2020.11.25.20237883.abstract
AB Introduction A single center open label phase II randomised control trial was done to assess the pathogen and host-intrinsic factors influencing clinical and immunological benefits of passive immunization using convalescent plasma therapy (CPT), in addition to standard of care (SOC) therapy in severe COVID-19 patients, as compared to patients only on SOC therapy.Methods Convalescent plasma was collected from patients recovered from COVID-19 following a screening protocol which also included measuring plasma anti SARS-CoV2 spike IgG content. Retrospectively, neutralizing antibody content was measured and proteome was characterized by LC-MS/MS for all convalescent plasma units that were transfused to patients. Severe COVID-19 patients with evidence for acute respiratory distress syndrome (ARDS) with PaO2/FiO2 ratio 100-300 (moderate ARDS) were recruited and randomised into two parallel arms of SOC and CPT, N=40 in each arm. Peripheral blood samples were collected on the day of enrolment (T1) followed by day3/4 (T2) and day 7 (T3). RT-PCR and sequencing was done for SARS-CoV2 RNA isolated from nasopharyngeal swabs collected at T1. A panel of cytokines and neutralizing antibody content were measured in plasma at all three timepoints. Patients were followed up for 30 days post-admission to assess the primary outcomes of all cause mortality and immunological correlates for clinical benefits.Results While across all age-groups no statistically significant clinical benefit was registered for patients in the CPT arm, significant immediate mitigation of hypoxia, reduction in hospital stay as well as survival benefit was recorded in severe COVID-19 patients with ARDS aged less than 67 years receiving convalescent plasma therapy. In addition to its neutralizing antibody content a prominent effect of convalescent plasma on attenuation of systemic cytokine levels possibly contributed to its benefits.Conclusion Precise targeting of severe COVID-19 patients is necessary for reaping the clinical benefits of convalescent plasma therapy.Clinical trial registration Clinical Trial Registry of India No. CTRI/2020/05/025209Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trial Registry of India No. CTRI/2020/05/025209Funding StatementD.G. acknowledges funding for the RCT and associated immune monitoring studies from Council of Scientitific Industrial Research (CSIR), Govt. of India (MLP-129); R.P. acknowledge funding from CSIR (MLP-2005) and Fondation Botnar.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The randomized control trial (RCT) on passive immunization with convalescent plasma therapy and all associated studies were done with informed consent from the patients according to the recommendations and ethical approval from the Institutional Review Boards of all the concerned institutions, viz. CSIR-Indian Institute of Chemical Biology, Kolkata, India (IICB/IRB/2020/3P), Medical College Hospital, Kolkata (MC/KOL/IEC/NON-SPON/710/04/2020), India and Infectious Disease & Beleghata General Hospital (ID & BG Hospital), Kolkata, India (IDBGH/Ethics/2429). The RCT was approved by Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India (approval no. CT/BP/09/2020) and registered with Clinical Trial Registry of India (CTRI, No. CTRI/2020/05/025209), under Indian Council of Medical Research, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the manuscript are available with the corresponding author.